Media headlines about BioTelemetry (NASDAQ:BEAT) have trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioTelemetry earned a news impact score of 0.06 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 47.1320604427624 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- $81.43 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter (americanbankingnews.com)
- Stocks With Rising Relative Strength: BioTelemetry (finance.yahoo.com)
- BioTelemetry, Inc. (BEAT) Expected to Announce Earnings of $0.24 Per Share (americanbankingnews.com)
- BioTelemetry : Research and AMRA Raise the Standard for Medical Imaging in NASH/NAFLD Clinical Trials (4-traders.com)
- BioTelemetry, Inc. Forecasted to Earn Q3 2017 Earnings of $0.18 Per Share (BEAT) (americanbankingnews.com)
BioTelemetry (NASDAQ BEAT) opened at 29.55 on Monday. BioTelemetry has a 12-month low of $15.25 and a 12-month high of $39.20. The firm has a market cap of $956.24 million, a P/E ratio of 19.83 and a beta of 0.68. The firm’s 50-day moving average price is $32.57 and its 200 day moving average price is $32.33.
BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The firm had revenue of $58.10 million for the quarter, compared to analysts’ expectations of $58.39 million. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 earnings per share. Analysts forecast that BioTelemetry will post $0.95 earnings per share for the current fiscal year.
BEAT has been the topic of several analyst reports. Off Wall Street initiated coverage on BioTelemetry in a research note on Friday, September 15th. They issued a “sell” rating on the stock. Benchmark Co. upped their price objective on BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, July 19th. BidaskClub lowered BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Lake Street Capital reiterated a “buy” rating and issued a $50.00 price objective (up from $35.00) on shares of BioTelemetry in a research note on Friday, July 14th. Finally, SunTrust Banks, Inc. initiated coverage on BioTelemetry in a research note on Monday, October 23rd. They issued a “buy” rating and a $41.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. BioTelemetry currently has an average rating of “Buy” and an average price target of $42.86.
COPYRIGHT VIOLATION WARNING: “BioTelemetry (BEAT) Earning Somewhat Favorable Press Coverage, Analysis Shows” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/10/30/biotelemetry-beat-earning-somewhat-favorable-press-coverage-analysis-shows.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
What are top analysts saying about BioTelemetry Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioTelemetry Inc. and related companies.